Biotechnology Investment Incentive Tax Credit - Conversion to Grant Program
HB0400 converts Maryland’s Biotechnology Investment Incentive Tax Credit into a Biotechnology Investment Incentive Grant Program administered by the Department of Commerce. The bill transfers the existing program provisions from the Tax-General Article to the Economic Development Article, renames the incentive as a grant rather than a tax credit, and keeps the core eligibility framework for investors and biotechnology companies largely intact. Qualified investors would still need to apply in advance, receive an initial eligibility certificate, make an investment in a qualified Maryland biotechnology company, and then provide proof of the investment before the Department awards the grant.
The bill preserves the program’s basic policy goal of encouraging early-stage biotechnology investment in Maryland, but changes the mechanism from a tax credit claimed against income tax to a grant paid out by the Department. It also creates a new special, nonlapsing Biotechnology Investment Incentive Grant Program Fund, requires a $10 million annual appropriation, and directs the Department to disburse approved grants within 90 days after determining the investment was made. The bill adds a subtraction modification for grant amounts received by individuals and corporations, so the grant itself would not be taxed as income under Maryland law.
The bill keeps several existing program limits and conditions, including caps on the percentage and maximum grant amount, special enhanced terms for certain rural counties and regional institution strategic enterprise zones, and a statewide aggregate limit tied to annual appropriations. It also retains recapture and revocation provisions if the investor sells the interest too soon, the company stops operating in Maryland, or the company fails to qualify within two months after receiving the investment. The bill repeals the old tax-credit-specific electronic filing requirement and updates cross-references throughout the Economic Development and Tax-General Articles to reflect the new grant structure.
The general sentiment reflected in the bill text is supportive of continued biotechnology-sector incentives, with the conversion framed as a modernization of an existing economic development tool rather than a policy reversal. Because there are no committee transcripts or recorded votes provided, there is no direct evidence of debate, but the structure suggests an effort to preserve the program while making funding more direct and predictable. The main policy choice is administrative and fiscal: whether the state should continue supporting biotech investment through a grant program funded in the budget instead of through a tax credit claimed on returns.
Notable points of potential contention include the mandatory $10 million annual appropriation, the prohibition on reducing that appropriation in the budget as approved by the General Assembly, and the shift from tax expenditures to direct spending. Stakeholders focused on budget flexibility, tax administration, or program oversight may scrutinize the new fund structure and the Department’s authority to award and revoke grants. Biotechnology companies, early-stage investors, and economic development advocates are the most likely supporters, while fiscal watchdogs or budget writers may focus on the cost and the continuing state commitment to the program.
HB0400 would repeal the Biotechnology Investment Incentive Tax Credit framework in the Tax-General Article and reestablish it as a grant program in the Economic Development Article, with corresponding cross-reference changes in related opportunity zone and income tax provisions. It would create a dedicated grant fund, require annual appropriations, authorize grant disbursement by the Department of Commerce, and add income tax subtraction modifications so grant proceeds are excluded from Maryland taxable income for individuals and corporations. The bill also preserves recapture, revocation, reporting, and eligibility rules that govern investors and qualified biotechnology companies.
The bill appears generally favorable toward biotechnology investment and economic development, with the conversion to a grant program presented as a continuation of the existing incentive rather than a substantive rollback. No committee testimony or votes are provided, so there is no recorded opposition or support in the supplied materials. Based on the text alone, the measure seems designed to maintain bipartisan economic-development support while changing the delivery mechanism from tax credits to grants.
The most likely points of contention are fiscal and administrative: the bill requires a $10 million annual appropriation, creates a nonlapsing fund, and limits the Governor’s ability to reduce the appropriation once approved by the General Assembly. Some may also question whether converting a tax credit into a grant improves transparency and timing, or instead shifts the program into a more direct spending commitment. Supporters are likely to be biotechnology firms, investors, and economic development advocates; critics may include budget hawks or those concerned about state spending and program oversight.